Latest News

• share
• favorite_border

SMA is Leading Genetic Cause of Infant and Toddler Mortality.

• share
• favorite_border

Experienced leaders in business, media, and law, join the SMA Foundation’s Board of Directors.

• share
• favorite_border

SMA Foundation and Rules-Based Medicine collaborate on Biomarker Panels to Guide SMA Therapeutic Development.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation, a nonprofit organization dedicated to accelerating the development of a treatment for SMA, is pleased to announce the completion of a pilot study to identify Biomarkers for Spinal Muscular Atrophy (BforSMA) and the discovery of over 400 candidate biomarkers.

• share
• favorite_border

PTC Therapeutics, Inc. (PTC) and the Spinal Muscular Atrophy (SMA) Foundation today announced the expansion of their research collaboration in which the SMA Foundation will provide up to $8.5 million in funding to PTC. This is the second continuation of the collaboration to fund a series of research projects initiated in 2006 to identify and optimize compounds with the potential to treat SMA by increasing production of the survival motor neuron (SMN) protein. The lack of the SMN protein causes SMA. Total funding for the initiative is now $11.7 million.

• share
• favorite_border

The Spinal Muscular Atrophy (SMA) Foundation, a nonprofit organization dedicated to accelerating the development of a treatment for SMA, is pleased to announce the completion of enrollment for a pilot study of Biomarkers for Spinal Muscular Atrophy (BforSMA).

• share
• favorite_border

The Spinal Muscular Atrophy (SMA) Foundation, a nonprofit organization dedicated to accelerating the development of a treatment for SMA, is pleased to announce the launch of a pilot study of Biomarkers for Spinal Muscular Atrophy (BforSMA).

• share
• favorite_border

Investigators meet to advance clinical research for SMA, the leading genetic cause of infant and toddler mortality.

• share
• favorite_border

Biomarker discovery program for the leading genetic killer of infants and toddlers.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation announces the addition of Ivan Lieberburg, Ph.D., M.D. and Edward Kaye, M.D. to its Scientific Advisory Board. They join a distinguished group of business and scientific leaders who help formulate and execute the SMA Foundation's drug discovery programs.

• share
• favorite_border

The Spinal Muscular Atrophy (SMA) Foundation announced today that it has received the 2006 Advocacy Award of Merit from the Child Neurology Foundation (CNF). The award was presented to the SMA Foundation during the Annual Meeting of the Child Neurology Society in Pittsburgh on October 20

• share
• favorite_border

The Spinal Muscular Atrophy Foundation today announced that they have initiated a research and development collaboration with PTC Therapeutics, Inc. (PTC). The collaboration is designed to leverage PTC's proprietary Gene Expression Modulation by Small-molecules (GEMS) technology to identify and develop new small molecule therapeutics for use in the treatment or prevention of spinal muscular atrophy (SMA).

• share
• favorite_border

The Spinal Muscular Atrophy Foundation announced the completion of a new licensing agreement that will facilitate access to intellectual property fundamental to drug discovery efforts for the disease.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation announced an agreement today with Regeneron Pharmaceuticals, Inc. to develop new animal models of spinal muscular atrophy, the leading genetic cause of mortality in infants and toddlers.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation today announced the addition of six members to its Scientific Advisory Board. The new advisors were specifically sought for the wealth of experience they bring to bear on Foundation efforts to advance drug development in spinal muscular atrophy.

• share
• favorite_border

The recipient of this year's Young Investigator Award in Spinal Muscular Atrophy is Mustafa Sahin from Children's Hospital Boston. Dr. Sahin will conduct new research on SMA -- the leading genetic killer of infants and toddlers and a disease which has no known treatment or cure.

• share
• favorite_border

Researchers at Columbia University have received more than $3 million in funding from the Spinal Muscular Atrophy Foundation to conduct research on spinal muscular atrophy, a neuromuscular disease that is the leading genetic killer of infants and toddlers.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation, a nonprofit organization dedicated to finding a treatment or cure for spinal muscular atrophy "“ the leading genetic killer of infants and toddlers "“ announced that is has funded more than $15 million in research in the last 18 months.

• share
• favorite_border

The Jackson Laboratory is pleased to announce that it has received support from the Spinal Muscular Atrophy Foundation to make available the first group of mouse models for spinal muscular atrophy (SMA), a neuromuscular disease and the leading genetic cause of death among infants and toddlers.

• share
• favorite_border

Researchers at Columbia University, Children's Hospital Boston and The Children's Hospital of Philadelphia have established a clinical research network to study spinal muscular atrophy, the leading genetic killer of infants and toddlers.

• share
• favorite_border

CombinatoRx, Incorporated and the Spinal Muscular Atrophy Foundation today announced that they have initiated a research and development collaboration aimed at identifying novel combination drugs for the treatment of spinal muscular atrophy.

• share
• favorite_border

Curis, Inc., a therapeutic drug development company, today announced that it has received a $5.4 million, three-year grant from the Spinal Muscular Atrophy Foundation to identify therapeutic compounds to treat spinal muscular atrophy.

• share
• favorite_border

Funding from the Spinal Muscular Atrophy Foundation has brought Dr. Yimin Hua to Cold Spring Harbor Laboratory, where he will work in the lab of Dr. Adrian Krainer to advance research into the cures of spinal muscular atrophy (SMA), the leading genetic killer of infants and toddlers.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation announces that two new members have joined its Scientific Advisory Board today. The new members are Geoffrey Duyk, Managing Director of TPG Ventures and Gerald Fischbach, Executive Vice President and Dean of the Faculty of Columbia University Medical Center.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation, in partnership with the American Academy of Neurology Foundation, today announced that they are seeking grant applications from investigators working on innovative spinal muscular atrophy research projects.

• share
• favorite_border

Loren Eng, Founder and President of the Spinal Muscular Atrophy Foundation, testified on Capitol Hill. Eng urged Congress for increased funding and support for the National Institute of Health research programs on Spinal Muscular Atrophy.

• share
• favorite_border

The Spinal Muscular Atrophy Foundation today announced that it has awarded new research grants totaling $1.125 million to four outstanding Young Investigators specializing in research on Spinal Muscular Atrophy, the leading genetic killer of infants and toddlers.